Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab-Reference-Cited by-同舟云学术

Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab

Published:2020-08 Issue:4 Volume:9 Page:1533-1542
ISSN:2218-6751
Container-title:Translational Lung Cancer Research
language:
Short-container-title:Transl Lung Cancer Res

Author:

Banna Giuseppe Luigi,Signorelli Diego,Metro Giulio,Galetta Domenico,De Toma Alessandro,Cantale Ornella,Banini Marco,Friedlaender Alex,Pizzutillo Pamela,Garassino Marina Chiara,Addeo Alfredo

Publisher

AME Publishing Company

Subject

Oncology

Link

http://tlcr.amegroups.com/article/download/42273/pdf

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data;Discover Oncology;2024-07-24

2. Prognostic value of immunotherapy in advanced NSCLC based on baseline and dynamic changes in HALP;Biomolecules and Biomedicine;2024-07-14

3. Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities;Cancers;2024-04-15

4. Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer;BMC Cancer;2024-04-08

5. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: A Single Institutional Cohort Study;Technology in Cancer Research & Treatment;2024-01